This study examined how polymorphisms in the SCN2A gene relate to response to Valproic Acid in children with epilepsy. Pakistani children aged 1-12 who had experienced at least two seizures and were newly started on Valproic Acid were included. It was a non-phase study that has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Epileptic Pakistani individuals of age between 1 to 12 years of either sex * Each patient had experienced two or more clinically confirmed, spontaneous epileptic seizures in the past. * Newly diagnosed patients started VPA 20 mg/kg (drug of the same brand was used for every patient throughout the study). Exclusion Criteria: * Patients taking any other anti-epileptic drug. * Patients taking medications that interact with VPA. * Patients with moderate or severe systemic diseases